KBI Biopharma Inc. sell "Selexis® SUREtechnology Platform™"

The Selexis® SUREtechnology Platform™ is KBI Biopharma's proven solution for high-yield, high-quality CHO-based cell line development, built to accelerate biologics programs and overcome expression challenges with stable, scalable production even for complex proteins. It features the proprietary SURE CHO-M™ cell line optimized for strong, stable expression, transposase-enabled gene integration for precise, reproducible performance, and suitability for monoclonal antibodies, Fc-fusion proteins, bispecifics, and other novel biologics, with flexible packages spanning early discovery through late-stage development, drawing on decades of complex biologics experience to improve molecule developability from the start.